S Rogers1, A Stauffer2, N Lomax3, S Alonso3, B Eberle3, S Gomez Ordoñez3, T Lazeroms3, E Kessler3, M Brendel4, L Schwyzer2, O Riesterer3,5. 1. Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. susanne.rogers@ksa.ch. 2. Department of Neurosurgery, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. 3. Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. 4. Department of Neuroradiology, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. 5. Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Abstract
PURPOSE: The outcomes of five fraction stereotactic radiotherapy (hfSRT) following brain metastasectomy were evaluated and compared with published series. METHODS: 30 Gy in 5 fractions HfSRT prescribed to the surgical cavity was reduced to 25 Gy if the volume of 'brain-GTV' receiving 20 Gy exceeded 20 cm3. Endpoints were local recurrence, nodular leptomeningeal recurrence, new brain metastases and radionecrosis. The literature was searched for reports of clinical and dosimetric outcomes following postoperative hfSRT in 3-5 fractions. RESULTS: 39 patients with 40 surgical cavities were analyzed. Cavity local control rate at 1 year was 33/40 (82.5%). 3 local failures followed 30 Gy/5 fractions and 4 with 25 Gy/5 fractions. The incidence of leptomeningeal disease (LMD) was 7/40 (17.5%). No grade 3-4 toxicities, particularly no radionecrosis, were reported. The incidence of distant brain metastases was 15/40 (37.5%). The median overall survival was 15 months. Across 13 published series, the weighted mean local control was 83.1% (adjusted for sample size), the mean incidence of LMD was 14.9% (7-34%) and the mean rate of radionecrosis was 10.3% (0-20.6%). CONCLUSION: Postoperative hfSRT can be delivered with 25-30 Gy in 5 fractions with efficacy in excess of 82% and no significant toxicity when the dose to 'brain-GTV' does not exceed 20 cm3.
PURPOSE: The outcomes of five fraction stereotactic radiotherapy (hfSRT) following brain metastasectomy were evaluated and compared with published series. METHODS: 30 Gy in 5 fractions HfSRT prescribed to the surgical cavity was reduced to 25 Gy if the volume of 'brain-GTV' receiving 20 Gy exceeded 20 cm3. Endpoints were local recurrence, nodular leptomeningeal recurrence, new brain metastases and radionecrosis. The literature was searched for reports of clinical and dosimetric outcomes following postoperative hfSRT in 3-5 fractions. RESULTS: 39 patients with 40 surgical cavities were analyzed. Cavity local control rate at 1 year was 33/40 (82.5%). 3 local failures followed 30 Gy/5 fractions and 4 with 25 Gy/5 fractions. The incidence of leptomeningeal disease (LMD) was 7/40 (17.5%). No grade 3-4 toxicities, particularly no radionecrosis, were reported. The incidence of distant brain metastases was 15/40 (37.5%). The median overall survival was 15 months. Across 13 published series, the weighted mean local control was 83.1% (adjusted for sample size), the mean incidence of LMD was 14.9% (7-34%) and the mean rate of radionecrosis was 10.3% (0-20.6%). CONCLUSION: Postoperative hfSRT can be delivered with 25-30 Gy in 5 fractions with efficacy in excess of 82% and no significant toxicity when the dose to 'brain-GTV' does not exceed 20 cm3.
Authors: Kamran A Ahmed; Jessica M Freilich; Yazan Abuodeh; Nicholas Figura; Neha Patel; Siriporn Sarangkasiri; Prakash Chinnaiyan; Hsiang-Hsuan Michael Yu; Arnold B Etame; Nikhil G Rao Journal: J Neurooncol Date: 2014-03-07 Impact factor: 4.130
Authors: Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316
Authors: R A Patchell; P A Tibbs; W F Regine; R J Dempsey; M Mohiuddin; R J Kryscio; W R Markesbery; K A Foon; B Young Journal: JAMA Date: 1998-11-04 Impact factor: 56.272
Authors: Zachary A Kohutek; Yoshiya Yamada; Timothy A Chan; Cameron W Brennan; Viviane Tabar; Philip H Gutin; T Jonathan Yang; Marc K Rosenblum; Åse Ballangrud; Robert J Young; Zhigang Zhang; Kathryn Beal Journal: J Neurooncol Date: 2015-08-26 Impact factor: 4.130
Authors: Hany Soliman; Mark Ruschin; Lilyana Angelov; Paul D Brown; Veronica L S Chiang; John P Kirkpatrick; Simon S Lo; Anita Mahajan; Kevin S Oh; Jason P Sheehan; Scott G Soltys; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-04 Impact factor: 7.038
Authors: Anita Mahajan; Salmaan Ahmed; Mary Frances McAleer; Jeffrey S Weinberg; Jing Li; Paul Brown; Stephen Settle; Sujit S Prabhu; Frederick F Lang; Nicholas Levine; Susan McGovern; Erik Sulman; Ian E McCutcheon; Syed Azeem; Daniel Cahill; Claudio Tatsui; Amy B Heimberger; Sherise Ferguson; Amol Ghia; Franco Demonte; Shaan Raza; Nandita Guha-Thakurta; James Yang; Raymond Sawaya; Kenneth R Hess; Ganesh Rao Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316